Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

A Pilot Study of F-18 Fluciclovine-PET/CT as A Diagnostic Tool for Bone Metastases in Patients With Hormonal Sensitive and Resistant Prostate Adenocarcinoma

Determine diagnostic accuracy of Axumin-PET positive bone lesion by confirmatory bone biopsy.

Inclusion Criteria:

1. Male
2. Be ≥ 18 years of age
3. Diagnosed with prostate cancer
4. Be willing and able to provide informed consent
5. Be informed of the investigational nature of this study

Exclusion Criteria:

1. Having a history of severe claustrophobia
2. Weight exceeding 400lbs